Genegobio Inc.

Bridging the gap between R&D and localized production. We facilitate the seamless integration of advanced therapeutics and diagnostics into high-growth markets, providing the regulatory, technical, and operational infrastructure required for immediate impact.

 

Below is our services of key issues and corresponding strategies:

​

I. Common Issues and Solutions in Drug Development

1. High Costs and Long Timelines

   • Issue: On average, new drug development takes 10-15 years and costs over $2 billion (DiMasi, 2021), with a high failure rate (about 90% of drugs in clinical stages fail to reach the market).

   • Solutions:

     • Modular Developmen

     • CRO Collaboration

     • Adaptive Clinical Trial Design:

2. Complexity of Clinical Trials

   • Issue: Difficulties in patient recruitment (e.g., rare diseases) and unclear endpoint metrics.

   • Solutions:

     • Real-World Evidence (RWE)

     • Decentralized Clinical Trials (DCT)

     • Biomarker Stratification

3. Regulatory Compliance Challenges

   • Issue: Increasingly stringent FDA/EMA requirements 

   • Solutions:

     • Early Communication (Pre-IND Meetings)

     • Quality by Design (QbD)

4. Intellectual Property Protection

   • Issue: Patent cliffs and risks of compulsory licensing in emerging markets

   • Solutions:

     • Patent Thicket Strategy

     • Data Exclusivity

​

II. Shared Challenges and Cross-Sector Strategies

1. Funding Shortages

   • Strategies:

     • Risk-Sharing Models

     • Government Funding

     • Genegobio's Co-Investment

2. Barriers to Interdisciplinary Collaboration

   • Strategies:

     • Digital Collaboration Platforms

     • Our partnership database

3. Market Access Uncertainty

   • Strategies:

     • Parallel Submissions

     • Early HTA Involvement

     • Our market entry strategy